Meghji Mohsin Y 4
4 · bioAffinity Technologies, Inc. · Filed Mar 7, 2023
Insider Transaction Report
Form 4
Meghji Mohsin Y
Director
Transactions
- Conversion
Common Stock, par value $0.007
2022-09-06$3.67/sh+40,907$150,129→ 69,478 total - Conversion
Series A Convertible Preferred Stock
2022-09-06−286,349→ 0 totalExercise: $3.67→ Common Stock (40,907 underlying)
Footnotes (2)
- [F1]The number of shares of common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer") and the conversion or exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the Issuer's Common Stock, which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO").
- [F2]In connection with the IPO closing on September 6, 2022, the 286,349 shares of Series A Convertible Preferred Stock owned by Mr. Meghji automatically converted at the then-effective 1 for 7 conversion rate (as adjusted for the Issuer's 1-for-7 reverse stock split) into 40,907 fully paid and nonassessable shares of Common Stock. The Series A Convertible Preferred Stock had no expiration date.